Literature DB >> 22660873

Psoriasis: evolving treatment for a complex disease.

Jennifer Villaseñor-Park1, David Wheeler, Lisa Grandinetti.   

Abstract

The cutaneous manifestations of psoriasis can vary in morphology and severity, and therapy should be tailored accordingly. Biologic agents are important new options for treating patients with the most severe forms of the disease. All physicians should be aware that severe psoriasis may increase cardiovascular morbidity and the risk of death, and preventive strategies for patients with severe disease should be considered.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22660873     DOI: 10.3949/ccjm.79a.11133

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  12 in total

Review 1.  Psoriasis: female skin changes in various hormonal stages throughout life--puberty, pregnancy, and menopause.

Authors:  Romana Ceovic; Marko Mance; Zrinka Bukvic Mokos; Maja Svetec; Kresimir Kostovic; Daska Stulhofer Buzina
Journal:  Biomed Res Int       Date:  2013-12-28       Impact factor: 3.411

Review 2.  New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.

Authors:  Anthony A Gaspari; Stephen Tyring
Journal:  Dermatol Ther       Date:  2015 Jul-Aug       Impact factor: 2.851

3.  Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice.

Authors:  Shuangshuang Zhang; Xiangdong Liu; Lihong Mei; Hongfeng Wang; Fang Fang
Journal:  BMC Complement Altern Med       Date:  2016-08-31       Impact factor: 3.659

Review 4.  A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis.

Authors:  Molly Campa; Bobbak Mansouri; Richard Warren; Alan Menter
Journal:  Dermatol Ther (Heidelb)       Date:  2015-12-29

5.  Prokineticin 2 Plays a Pivotal Role in Psoriasis.

Authors:  Xiaoqin He; Chuanbin Shen; Qiumin Lu; Jiong Li; Yuquan Wei; Li He; Ruizhen Bai; Jie Zheng; Ning Luan; Zhiye Zhang; Mingqiang Rong; Ren Lai
Journal:  EBioMedicine       Date:  2016-10-19       Impact factor: 8.143

6.  Combination Therapy of Acarbose and Cyclosporine a Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis in Mice.

Authors:  Hsin-Hua Chen; Chi-Chien Lin; Yu-Tang Tung; Ya-Hsuan Chao; Wen-Ching Huang; Po-Ying Lee
Journal:  Molecules       Date:  2020-04-16       Impact factor: 4.411

7.  Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.

Authors:  Wencui Chen; Guisheng Ren; Ke Zuo; Xianghua Huang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

8.  Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations.

Authors:  Paolo Gisondi; Marina Talamonti; Andrea Chiricozzi; Stefano Piaserico; Paolo Amerio; Anna Balato; Federico Bardazzi; Piergiacomo Calzavara Pinton; Anna Campanati; Angelo Cattaneo; Paolo Dapavo; Clara De Simone; Valentina Dini; Maria C Fargnoli; Maria L Flori; Marco Galluzzo; Claudio Guarneri; Claudia Lasagni; Francesco Loconsole; Ada Lo Schiavo; Piergiorgio Malagoli; Giovanna Malara; Santo R Mercuri; Maria L Musumeci; Luigi Naldi; Manuela Papini; Aurora Parodi; Concetta Potenza; Francesca Prignano; Franco Rongioletti; Luca Stingeni; Rossana Tiberio; Marina Venturini; Luca Bianchi; Antonio Costanzo; Francesco Cusano; Giampiero Girolomoni; Anna M Offidani; Ketty Peris
Journal:  Dermatol Ther (Heidelb)       Date:  2021-01-11

9.  Chitosan-based nanoformulated (-)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis.

Authors:  Jean Christopher Chamcheu; Imtiaz A Siddiqui; Vaqar M Adhami; Stephane Esnault; Dhruba J Bharali; Abiola S Babatunde; Stephanie Adame; Randall J Massey; Gary S Wood; B Jack Longley; Shaker A Mousa; Hasan Mukhtar
Journal:  Int J Nanomedicine       Date:  2018-07-20

10.  Fisetin, a 3,7,3',4'-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models.

Authors:  Jean Christopher Chamcheu; Stephane Esnault; Vaqar M Adhami; Andrea L Noll; Sergette Banang-Mbeumi; Tithi Roy; Sitanshu S Singh; Shile Huang; Konstantin G Kousoulas; Hasan Mukhtar
Journal:  Cells       Date:  2019-09-15       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.